Trial Profile
Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Histamine dihydrochloride (Primary) ; Interleukin-2
- Indications Acute myeloid leukaemia
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms RE:MISSION
- Sponsors Immune Pharmaceuticals Inc; Meda Pharma GmbH & Co KG
- 16 Dec 2021 This trial has been completed in France, as per European Clinical Trials Database record.
- 02 Feb 2019 The trial has been discontinued in United Kingdom, as per European Clinical Trials Database record.
- 09 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.